Nkam I, Langlois-Thery S, Dollfus S, Petit M
Groupe de recherche sur la schizophrénie, Centre Hospitalier du Rouvray, Sotteville-les-Rouen.
Encephale. 1997 Sep-Oct;23(5):358-63.
Coined by Sifneos in 1972, alexithymia refers to a relative narrowing in emotional functioning, an inability to find appropriate words to describe their emotions and, a poverty of fantasy life. Although initially described in the context of psychosomatic illness, alexithymic characteristics may be observed in patients with a wide range of medical and psychiatric disorders: Parkinson disease, depression, anxiety, substance abuse and eating disorders. Flattening of affect and poverty of speech, major negative symptoms, referred to chronic schizophrenia: there is a lack of outward display of emotion. Accordingly, some disturbances of alexithymia's scores would be expected in schizophrenic patients. The purpose of this study was to estimate and compare the prevalence of alexithymia in deficit and non-deficit schizophrenia. The term "deficit symptoms" may be used as Carpenter, to refer specifically to those negative symptoms that are not considered secondary. The influence of patients' symptoms has also been studied on alexithymia scores: negative and positive symptoms of schizophrenia, depression, anxiety, anhedonia and effects of neuroleptics. Twenty-five patients, meeting DSM III-R criteria for schizophrenia have been studied. All of them treated by neuroleptics, were in a stable clinical status for at least one month. The patients have been categorized into deficit (n = 12) and non-deficit (n = 13) subgroups by one trained psychiatrist (SD), using the Schedule for the Deficit Syndrome. The subjects have been assessed by the same rater (IN), blind to deficit status, using six rating scales: Beth Israel Questionnaire (BIQ) and Toronto Alexithymia Scale (TAS) for alexithymia, Positive and Negative Syndrome Scale (PANSS), Montgomery and Asberg Depression Rating Scale (MADRS), revised Physical Anhedonia Scale (PAS), and finally, Extrapyramidal Symptom Rating Scale (ESRS). Using TAS, alexithymic characteristics were more prevalent in the deficit subgroup as compared to non-deficit subgroup (83% versus 30.76%; p < 0.01). Significant correlations were observed in the non-deficit subgroup between: TAS and anxiety (r = 0.743; p < 0.01), TAS and depression (r = 0.568; p < 0.05), BIQ and blunted affect (r = 0.636; p < 0.02), BIQ and poverty of speech (r = 0.629; p < 0.02). These correlations were not significant in the deficit group of patients. Alexithymia in schizophrenic patients seems to be a trait characteristic in deficit patients, and a state related to many symptoms, such as flattening of affect, poverty of speech, depression and anxiety in nondeficit patients.
述情障碍由西夫neos于1972年提出,指情感功能相对受限,无法找到合适的词语来描述自己的情绪,以及幻想生活匮乏。虽然最初是在身心疾病的背景下描述的,但在患有各种医学和精神疾病的患者中都可能观察到述情障碍的特征:帕金森病、抑郁症、焦虑症、药物滥用和饮食失调。情感平淡和言语匮乏是慢性精神分裂症的主要阴性症状:缺乏情感的外在表现。因此,预计精神分裂症患者会出现一些述情障碍评分的紊乱。本研究的目的是评估和比较缺陷型和非缺陷型精神分裂症中述情障碍的患病率。“缺陷症状”一词可如卡彭特所使用的那样,专门指那些不被视为继发性的阴性症状。还研究了患者症状对述情障碍评分的影响:精神分裂症的阴性和阳性症状、抑郁症、焦虑症、快感缺失以及抗精神病药物的作用。对25名符合DSM III-R精神分裂症标准的患者进行了研究。他们都接受了抗精神病药物治疗,且临床状态稳定至少一个月。由一名经过培训的精神科医生(SD)使用缺陷综合征量表将患者分为缺陷型(n = 12)和非缺陷型(n = 13)亚组。由同一名评分者(IN)在不知道缺陷状态的情况下,使用六个评定量表对受试者进行评估:用于述情障碍的贝斯以色列问卷(BIQ)和多伦多述情障碍量表(TAS)、阳性和阴性症状量表(PANSS)、蒙哥马利和阿斯伯格抑郁评定量表(MADRS)、修订的身体快感缺失量表(PAS),以及最后一个锥体外系症状评定量表(ESRS)。使用TAS量表时,与非缺陷亚组相比,缺陷亚组中述情障碍特征更为普遍(83%对30.76%;p < 0.01)。在非缺陷亚组中观察到显著相关性:TAS与焦虑(r = 0.743;p < 0.01)、TAS与抑郁(r = 0.568;p < 0.05)、BIQ与情感迟钝(r = 0.636;p < 0.02)、BIQ与言语匮乏(r = 0.629;p < 0.02)。这些相关性在缺陷组患者中不显著。精神分裂症患者的述情障碍在缺陷型患者中似乎是一种特质特征,而在非缺陷型患者中是与许多症状相关的一种状态,如情感平淡、言语匮乏、抑郁和焦虑。